Nurx collects one other $22.5M for contraception & STI therapy deliveries

Nurx collects another $22.5M for birth control & STI treatment deliveries

Nurx, a startup recognized for on-line buy and supply of house well being assessments, contraception and different delicate therapies for ladies, has tacked on one other $22.5 million in Sequence C funding.

Closed in Might, the increase included new backers Trustbridge, Comcast Ventures and Wittington Ventures, in addition to prior backers Union Sq. Ventures and Kleiner Perkins Digital Progress Fund. This brings the corporate’s whole increase to $113 million.


HIMSS20 Digital

Be taught on-demand, earn credit score, discover merchandise and options. Get Began >>

Nurx made its identify by telehealth prescription and supply of contraception capsules, however not too long ago expanded its choices to incorporate different areas of reproductive well being. These embrace pre-exposure prophylaxis (PrEP) for HIV prevention, in addition to sexually transmitted an infection testing kits and coverings.

The corporate says it is at the moment offering its providers to greater than 300,000 folks month-to-month, accepting both medical health insurance or direct funds. It reported a spike of greater than 250,000 new affected person requests for contraception throughout the first half of the yr, in addition to greater than double the variety of regular requests for PrEP and STI therapy and testing – a lot of which it attributed to the COVID-19 pandemic.

“As the most important and most trusted digital observe for ladies’s well being, our crew was effectively positioned to leverage our momentum over the past yr and meet the surge in demand for our providers when the COVID-19 pandemic hit and uprooted our healthcare system,” Nurx CEO Varsha Rao mentioned in a press release. “I am happy with our crew’s dedication to offering our sufferers with the perfect care doable to allow them to stay safely at house.”

With this new development, Nurx predicts that it’s going to attain profitability by the early a part of subsequent yr.


Nurx mentioned that the funds would assist tackle rising demand for its choices, and would assist the introduction of latest providers for complications and migraines which might be set to launch later within the month. These would come with a web based session, a video examination to measure cognitive skills, customized therapy plans and common check-ins.

“Over the previous couple of months we have additional accelerated our affected person development throughout all of our providers,” Rao mentioned. “We’re excited to construct on our imaginative and prescient of treating and managing extra delicate healthcare wants that carry stigma and largely affect girls by launching our migraines and headache service.”


Nurx falls in step with the rising variety of consumer-friendly telehealth corporations offering discrete mail-order drugs, similar to Hims & Hers and Ro. Within the STI testing house, it competes like myLAB Field and Everlywell.

Each Nurx and the latter group of house well being testing startups sought to offer at-home COVID-19 testing shortly after the declaration of a public well being emergency within the U.S. This effort proved to be quick lived, nonetheless, after the FDA clarified that it had not but permitted any diagnostics for house use.

Supply hyperlink

Be the first to comment

Leave a Reply